Novel Alzheimer's Disease Drug Treatment

DESCRIPTION (provided by applicant): P2D Bioscience is developing the selective, non-addicting dopamine transport (DAT) inhibitor, PD2XXX, for the symptomatic treatment of Alzheimer's disease (AD). The core symptom of AD is short-term memory impairment. (DSM-IV) In preliminary studies, PD2XXX improved short term memory by over 110% in a well-accepted triple transgenic mouse model of AD (3xTg-AD). 3xTg-AD mice carry mutations of the APP, tau and presenilin 1 genes. Further, 3xTg-AD mice develop the age-dependent plaques and tangles characteristic of AD. Also, 3xTg-AD mice demonstrate the age-dependent cognitive decline observed in Alzheimer's patients. Therefore, our preliminary data indicate that PD2XXX significantly improved short- term memory in an AD model that mirrors the age-dependent development of Alzheimer's neuropathology as well as the cognitive deficits that characterize Alzheimer's clinical pathology. The long term goal of the proposed studies is to develop a safe and effective treatment for